JP2008512484A5 - - Google Patents

Download PDF

Info

Publication number
JP2008512484A5
JP2008512484A5 JP2007531364A JP2007531364A JP2008512484A5 JP 2008512484 A5 JP2008512484 A5 JP 2008512484A5 JP 2007531364 A JP2007531364 A JP 2007531364A JP 2007531364 A JP2007531364 A JP 2007531364A JP 2008512484 A5 JP2008512484 A5 JP 2008512484A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
heart
phosphatase inhibitor
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007531364A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008512484A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/032162 external-priority patent/WO2006029319A2/en
Publication of JP2008512484A publication Critical patent/JP2008512484A/ja
Publication of JP2008512484A5 publication Critical patent/JP2008512484A5/ja
Pending legal-status Critical Current

Links

JP2007531364A 2004-09-09 2005-09-08 心臓細胞におけるホスファターゼ活性の調節 Pending JP2008512484A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60821404P 2004-09-09 2004-09-09
PCT/US2005/032162 WO2006029319A2 (en) 2004-09-09 2005-09-08 Modulating phosphatase activity in cardiac cells

Publications (2)

Publication Number Publication Date
JP2008512484A JP2008512484A (ja) 2008-04-24
JP2008512484A5 true JP2008512484A5 (https=) 2008-10-23

Family

ID=36037020

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007531364A Pending JP2008512484A (ja) 2004-09-09 2005-09-08 心臓細胞におけるホスファターゼ活性の調節

Country Status (7)

Country Link
US (4) US9114148B2 (https=)
EP (1) EP1791432A4 (https=)
JP (1) JP2008512484A (https=)
CN (1) CN101056539B (https=)
AU (1) AU2005282352B2 (https=)
CA (1) CA2579519A1 (https=)
WO (1) WO2006029319A2 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1773303A2 (en) * 2004-05-25 2007-04-18 Chimeracore, Inc. Self-assembling nanoparticle drug delivery system
CA2638913A1 (en) * 2006-02-10 2007-09-07 The University Of Cincinnati Phosphatase inhibitor protein-1 as a regulator of cardiac function
CA2648581A1 (en) * 2006-04-07 2008-09-12 Chimeros, Inc. Compositions and methods for treating b- cell malignancies
GB2437893A (en) * 2006-07-25 2007-11-07 Celladon Corp Extended antegrade epicardial coronary infusion of adeno-associated viral vectors for gene therapy
CA2683063A1 (en) * 2007-04-09 2008-10-16 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
WO2008137681A2 (en) * 2007-05-02 2008-11-13 Intrexon Corporation Pp1 ligands
WO2010093784A2 (en) 2009-02-11 2010-08-19 The University Of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
JP5370969B2 (ja) * 2010-02-23 2013-12-18 国立大学法人金沢大学 心筋障害の検査方法
WO2012109570A1 (en) 2011-02-10 2012-08-16 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
CA2847888A1 (en) 2011-09-09 2013-03-14 Biomed Realty, L.P. Methods and compositions for controlling assembly of viral proteins
ES2926774T3 (es) 2013-03-15 2022-10-28 Univ North Carolina Chapel Hill Métodos y composiciones para vectores AAV de doble unión de glicano
US10907176B2 (en) 2015-01-14 2021-02-02 The University Of North Carolina At Chapel Hill Methods and compositions for targeted gene transfer
EP4653015A3 (en) * 2015-01-26 2025-12-31 Yale University COMPOSITIONS AND METHODS OF USE OF TYROSINE KINASE INHIBITORS
HK1248554A1 (zh) 2015-02-20 2018-10-19 Board Of Regents, The University Of Texas System 作为疫苗和载体的减毒衣原体的方法和组合物
ES2865487T3 (es) 2015-09-28 2021-10-15 Univ North Carolina Chapel Hill Métodos y composiciones para vectores virales que evaden los anticuerpos
US11246905B2 (en) 2016-08-15 2022-02-15 President And Fellows Of Harvard College Treating infections using IdsD from Proteus mirabilis
NZ756587A (en) 2017-03-15 2025-12-19 Univ North Carolina Chapel Hill Polyploid adeno-associated virus vectors and methods of making and using the same
EP3759218A4 (en) 2018-02-28 2021-12-08 The University of North Carolina at Chapel Hill PROCEDURES AND COMPOSITIONS FOR ANTIBODY ELIMINATING VIRUS VECTORS
AU2019247748A1 (en) 2018-04-03 2020-10-08 Ginkgo Bioworks, Inc. Antibody-evading virus vectors
EP3774852A1 (en) 2018-04-03 2021-02-17 Stridebio, Inc. Antibody-evading virus vectors
MX2020010465A (es) 2018-04-03 2021-01-08 Vectores de virus para direccionamiento a tejidos oftalmicos.
AR118465A1 (es) 2019-03-21 2021-10-06 Stridebio Inc Vectores de virus adenoasociados recombinantes
CN110367188A (zh) * 2019-04-04 2019-10-25 上海大学 心肌层转染慢病毒的小鼠模型的构建方法
EP4169535A1 (en) 2019-04-26 2023-04-26 The University of North Carolina at Chapel Hill Methods and compositions for dual glycan binding aav2.5 vector
JP2022551739A (ja) 2019-10-17 2022-12-13 ストライドバイオ，インコーポレイテッド ニーマン・ピック病ｃ型の治療のためのアデノ随伴ウイルスベクター
US12611436B2 (en) 2019-10-17 2026-04-28 Sarepta Therapeutics, Inc. AAV transfer cassette
EP4103214B1 (en) 2020-02-13 2026-04-29 Tenaya Therapeutics, Inc. Gene therapy vectors for treating heart disease
EP4192580A4 (en) * 2020-08-05 2025-06-18 AskBio Inc. Methods for treating heart disease and congestive heart failure and administration of AAV vectors
AU2021328475A1 (en) 2020-08-19 2023-03-16 Sarepta Therapeutics, Inc. Adeno-associated virus vectors for treatment of Rett syndrome
WO2022093769A1 (en) 2020-10-28 2022-05-05 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding aav2.5 vector
CN116490514A (zh) 2020-10-28 2023-07-25 北卡罗来纳-查佩尔山大学 用于双重聚糖结合aav2.5载体的方法和组合物
TW202242124A (zh) 2021-01-14 2022-11-01 美商史崔德生物公司 靶向ｔ細胞之ａａｖ載體
WO2022221529A1 (en) 2021-04-16 2022-10-20 Asklepios Biopharmaceutical, Inc. Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response
TW202342759A (zh) 2022-02-04 2023-11-01 美商史崔德生物公司 重組腺相關病毒載體及其使用方法
WO2024124019A2 (en) 2022-12-07 2024-06-13 Ginkgo Bioworks, Inc. Aav vectors targeting hematopoietic stem cells
KR20240173703A (ko) * 2023-06-05 2024-12-13 (주)벳바젠 포스포람반의 단백질 포스파타아제 1-매개 탈인산화 억제용　데코이 펩타이드를 암호화하는 뉴클레오타이드 및 ccn5 단백질 또는 이의 단편을 암호화하는 뉴클레오타이드를 포함하는 유전자 컨스트럭트 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589375A (en) * 1992-10-06 1996-12-31 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E. V. PTP 1D: a novel protein tyrosine phosphatase
US7745416B2 (en) * 1995-04-11 2010-06-29 The Regents Of The University Of California Method for in vivo regulation of cardiac muscle contractility
US20020040010A1 (en) * 1997-07-22 2002-04-04 Anthony Rosenzweig Use of agents to treat heart disorders
US20050095227A1 (en) * 1997-07-22 2005-05-05 The General Hospital Corporation Treating heart failure
WO2000022152A1 (en) * 1998-10-13 2000-04-20 Avigen, Inc. Compositions and methods for producing recombinant adeno-associated virus
WO2002055710A2 (en) * 2001-01-11 2002-07-18 Bayer Ag Regulation of human purple acid phosphatase
US20040214760A1 (en) * 2001-01-15 2004-10-28 Ramesh Gupta Inhibition pf protein-phosphatases for the treatment of heart failure
US20020159978A1 (en) * 2001-02-06 2002-10-31 James Allen Muscle-directed gene transfer by use of recombinant AAV-1 and AAV-6 virions
US7655467B2 (en) * 2003-11-14 2010-02-02 The University Of Washington Compositions and methods for systemic nucleic acid sequence delivery
CA2638913A1 (en) 2006-02-10 2007-09-07 The University Of Cincinnati Phosphatase inhibitor protein-1 as a regulator of cardiac function

Similar Documents

Publication Publication Date Title
JP2008512484A5 (https=)
Hulot et al. Gene therapy for the treatment of heart failure: promise postponed
Müller et al. Targeting the heart with gene therapy-optimized gene delivery methods
JP2007531564A (ja) 遺伝子発現を制御する埋め込み可能なシステム
JP2009525757A5 (https=)
EP4069849B1 (en) Liver-specific promoter and application thereof
KR20230084542A (ko) 플라코필린 2 유전자 치료 방법 및 조성물
US20160166651A1 (en) Systemic delivery of virus vectors encoding urocortin-2 and related genes to treat diabetes-related cardiac dysfunctions and congestive heart failure
EP1317289B1 (en) Dominant negative PLB mutant for use in treating cardiac disease
US20030072744A1 (en) Methods of altering cardiac cell phenotype
HK1222884A1 (zh) 用於治疗心力衰竭和增加心脏功能的不能产生环腺苷酸的腺苷酸环化酶和组合物和方法
Xu et al. Optimizing drug delivery for enhancing therapeutic efficacy of recombinant human endostatin in cancer treatment
JP2002533359A (ja) 組換えアデノ随伴ウイルスベクターを用いる、心筋細胞への効率的かつ安定なインビボでの遺伝子移入
CN1301181A (zh) 基因转移介导的血管生成疗法和血管内基因传递技术
EP1581241A2 (en) Stimulation of vascularization with vegf-b
ES2975422T3 (es) Proteínas con actividad cardioprotectora
CN115885043A (zh) 用于dwarf开放阅读框的腺相关病毒载体
Avril et al. Defining the success of cardiac gene therapy: how can nuclear imaging contribute?
Askari et al. Targeted gene therapy for the treatment of cardiac dysfunction
WO2018090042A1 (en) Methods of treating heart failure
JP2006514929A (ja) 冠動脈疾患の治療
US20250283080A1 (en) Gene therapy of hippo signaling improves heart function in a clinically relevant model
WO2025148391A1 (zh) 蛋白激酶a抑制肽及其用途
Foo et al. Gene Therapy for Heart Failure
Rubanyi Gene therapy—basic principles and the road from bench to bedside